Oncolytics Biotech Inc T.ONC

Roche enters into a definitive agreement to acquire Poseida

[spesestsemper]

Roche enters into a definitive agreement to acquire Poseida

[spesestsemper]

It would be a dream if oncolytics get a similar offer . They went from a little under $3 to 9 today . Similar outstanding shares

[Noteable]

A Phase 2 company with a platform technology that can address multiple solid tumors including those combined with CAR-T therapies is worth multiple billion$ , particularly when a Phase 1 CAR-T company does not have a therapy that can address solid cancers without bring combined with pelareorep

[spesestsemper]

I get your dedication to the company but this company was trading almost 3 times higher then oncoytics before this offer . That tells you something  . I would be estactic if they would come anywhere close to this offer . 

[Noteable]

That should tell you that ONCY is undervalued. Obviously you haven't figured that out or you wouldn't be stating the outlandish.

[inthno]

All it tells us at this moment.is that they are most interested in other companies. If we are so.good then why not onc. How many more trials and good results will it take. Even according.to.the company in their last cc.is that it will be about 1.5 years after the trial.starts. We can only.hope that all.the talk on this board pays off. So let's hope that at least a partnership is in the works

[Noteable]

Yes Da-man/inthno et al. we've already seen your drivel on Stktwits.

[Noteable]

With the pathway to Accelerated Approval (AA) open to ONCY and the FDA granting Replimmune's intratumorally (IT) delivered OV therapy Breakthrough Therapy Designation (BTD), ONCY's pelareorep 'second mouse' strategy leads the path towards gaining AA and BTD on ONCY's IV administered OV pelareorep, and in particular now gaining a much earlier AA than some think, as exampled

[Noteable]

Both Roche and Novartis seem "woke" to ONCY's potential with pelareorep's ability to synergize with other biologics like immune checkpoint inhibitors, bispecifics, ADCs, CAR-T therapies, as well as small molecules like CD4, CD6, and PARP inhibitors, as just several examples. Now that ONCY has the ACCELERATED APPROVAL and Breakthrough Therapy Designation open, the early approval

[Noteable]

This month both Roche and Novartis acquired early stage CAR-T therapy companies for bilions$. Now that both Roche and Novartis have CAR-T therapies that can only treat liquid cancers and not solid tumors, they are both likely circling ONCY for pelareorep's ability to "cure" solid tumors when combined with those therapies. And as stated, a Phase 2 company with a platform technology

[Noteable]

This month both Roche and Novartis acquired early stage CAR-T therapy companies for bilions$. Now that both Roche and Novartis have CAR-T therapies that can only treat liquid cancers and not solid tumors, they are both likely circling ONCY for pelareorep's ability to "cure" solid tumors when combined with those therapies. The proposed acquisition will establish a new core capability